恩替卡韦治疗乙型肝炎肝硬化临床疗效分析

目的:观察恩替卡韦治疗乙型肝炎肝硬化的疗效和安全性。方法:将患者分为乙型肝炎肝硬化组即A组和慢性乙型肝炎组即B组,均给予口服恩替卡韦0.5 mg/d,疗程72周。观察两组ALT复常率,HBVDNA阴转率,A组Child-Pugh评分情况及不良反应。结果:两组ALT复常率,HBVDNA阴转率随治疗延长而增加,两组比较无统计学意义。A组Child-Pugh评分明显下降。治疗中无明显不良反应。结论:恩替卡韦治疗乙型肝炎肝硬化疗效佳且安全性良好。

Clinical effect analysis of Enticavir in treatment of cirrhosis due to hepatitis B

Objective:To observe the effect and safety of Enticavir in treatment of cirrhosis due to hepatitis B.Methods:Divided the patients into cirrhosis group(group A) and chronic hepatitis B group(group B),give oral Entecavir 0.5mg/d for 72 weeks and observe ALT normalization rate,HBVDNA negative conversion rate of both group,Child-Pugh score of A group A,and adverse reactions.Results: ALT normalization rate and HBVDNA negative conversion rate both increase with the prolonged treatment.No statistical significance found in comparison of two groups.Child-Pugh score decrease obviously in A group.No adverse reactions happen in treatment.Conclusions: Entecavir has good effect and safety in treatment of cirrhosis due to hepatitis B.